Product
DAY101
2 clinical trials
2 indications
Indication
Low-grade gliomaIndication
Advanced Solid TumorClinical trial
FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2022-12-22
Clinical trial
A Phase I Study of Tovorafenib/DAY101 (Formerly TAK-580, MLN2480) for Children With Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31